Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Healthy Volunteers

Mescaline for Healthy Volunteers

13 papers and 2 clinical trials exploring mescaline as a treatment for healthy volunteers.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

13 papers
Open Accessmeta

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects

This systematic review (s=32) of healthy adult volunteers examined the pharmacokinetics of LSD, psilocybin, DMT, mescaline and 5-MeO-DMT. It found that LSD and psilocybin showed dose-related peak levels, while oral and intravenous DMT differed in ways that may matter clinically.

Published
May 29, 2026
Journal
Journal of Psychopharmacology
Authors
Hampsey, E., Martin, K., Kalfas, M., Benson, L., Wihlborg, S., Jelen, L., Young, A. H., Rucker, J.
Open Accessindividual

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

This psychometric analysis using the PES100 examined 816 measurements from healthy participants (n=386) across 15 controlled psychedelic studies of LSD, psilocybin, mescaline and DMT. It found that mystical oneness was strongly linked to feelings of luminous light and renewal, and moderately to strongly linked to ego disintegration, with these links increasing with dose.

Published
March 31, 2026
Journal
Religion, Brain & Behavior
Authors
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., Becker, A. M., Vizeli, P., Holze, F., Liechti, M. E.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants

This pharmacokinetic-pharmacodynamic analysis (n=46) of two Phase I trials of oral mescaline (100-800 mg) showed dose-proportional exposure with peak concentrations at 2 hours, a half-life of 3.5 hours, onset of effects around 1 hour post-dose, maximum effect intensity and duration ranging from 13% and 2.8 hours (100 mg) to 89% and 15 hours (800 mg), with 53% urinary excretion unchanged and 31% as the main metabolite, indicating at least 53% oral bioavailability.

Published
July 14, 2025
Journal
Clinical Pharmacokinetics
Authors
Mueller, L., Klaiber, A., Ley, L., Becker, A. M., Thomann, J., Luethi, D., Schmid, Y., Liechti, M. E.
Open Accessmeta

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

This systematic review (2024) and meta-analysis (s=131) examines the incidence of psychedelic-induced psychosis, focusing on individuals with schizophrenia. It finds an incidence of 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs, with 3.8% of UCT participants with schizophrenia developing long-lasting psychotic symptoms. It also reports that 13.1% of those with psychedelic-induced psychosis later developed schizophrenia.

Published
November 27, 2024
Journal
Molecular Psychiatry
Authors
Sabé, M., Sulstarova, A., Glangetas, A., De Pieri, M., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L., Seragnoli, F., Thorens, G., Zullino, D., Preller, K., Böge, K., Leucht, S., Correll, C. U., Solmi, M., Kaiser, S., Kirschner, M.
Open Accessindividual

Safety pharmacology of acute mescaline administration in healthy participants

This pooled analysis of two double‑blind, randomized, placebo‑controlled studies (48 participants, 96 administrations) found that single oral doses of mescaline 100–800 mg produced dose‑dependent increases in positive subjective effects with only moderate autonomic changes and no clinically significant liver, kidney or haematological abnormalities. Although nausea was dose‑limiting and small proportions experienced transient diastolic hypertension, tachycardia, fever or “flashbacks”, single doses up to 800 mg were considered safe with respect to acute psychological and physical harm in healthy participants in a controlled clinical setting.

Published
November 25, 2024
Journal
British Journal of Clinical Pharmacology
Authors
Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., Liechti, M. E.

Clinical Trials

2 trials
CompletedPhase I

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

This double-blind, placebo-controlled, 6-period crossover study (n=16) evaluated escalating oral mescaline doses (100–800 mg) and ketanserin pre-treatment in healthy volunteers aged 25–65.

Started
January 5, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04849013
CompletedPhase I

Comparative Acute Effects of LSD, Psilocybin and Mescaline

This double-blind, placebo-controlled, 4-period crossover study (n≈32) compared single doses of LSD 100 µg, psilocybin 20 mg, mescaline 300/500 mg and placebo in healthy volunteers to characterise acute subjective, physiological and neural effects.

Started
May 19, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04227756

Explore further

Search all Mescaline papers Search all Healthy Volunteers trials Full Mescaline profile Full Healthy Volunteers profile